Diabetogene RAD

Description: This invention relates to a protein whose expression is correlated with certain diabetes disease states, and may therefore play a key role in the etiology of the disease, or may be a marker that is symptomatic of certain forms of diabetes. The Rad gene encodes a novel member of the ras/GTPase gene family, which shares a 45-55% homology at the nucleotide level and a 33% homology at the amino acid level in the GTPase domain with other members of this family. The expression of Rad is increased in Type II but not Type I diabetes patients. Clinical & Commercial Utility: The Rad protein may represent an important target for drug discovery and/or therapeutics of diabetes and related disorders. Expression patterns of the Rad gene may also be used in diagnostic assays to determine a patient’s risk for developing diabetes. U.S. Patent No. 5,891,430 covers Rad protein molecules, and U.S. Patent No. 5,589,374 covers nucleic acids encoding Rad. U.S. Patent No. 6,326,141 claims methods of diagnosing risk for diabetes.
Joslin Diabetes Center is the owner of U.S. Patent Numbers: 5,891,430 5,589,374 6,326,141

Type of Offer: Licensing



« More Medical Patents

---